Luseogliflozin (hydrate)

Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM) [1][2].

Product Specifications

CAS Number

[1152425-66-5]

Product Name Alternative

TS 071 (hydrate)

UNSPSC

12352005

Target

SGLT

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/luseogliflozin-hydrate.html

Purity

99.20

Solubility

10 mM in DMSO

Smiles

OC[C@@H](S1)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1C2=C(OC)C=C(C)C(CC3=CC=C(OCC)C=C3)=C2.O

Molecular Formula

C23H32O7S

Molecular Weight

452.56

References & Citations

[1]Anthony Markham, et al. Luseogliflozin: first global approval. Drugs. 2014 Jun;74 (8) :945-50.|[2]Jun Shirakawa, et al. Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway. Diabetologia. 2020 Mar;63 (3) :577-587.